Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,384 shares of the biopharmaceutical company’s stock after purchasing an additional 2,234 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $21,428,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of REGN. International Assets Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the period. Swedbank AB acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $129,257,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after purchasing an additional 96,266 shares during the period. TD Asset Management Inc raised its position in Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after purchasing an additional 82,034 shares during the period. Finally, Icon Wealth Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on REGN shares. Citigroup began coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price for the company. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $738.00 on Monday. The stock has a market capitalization of $81.10 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 2.84 and a beta of 0.15. The business’s fifty day moving average price is $945.07 and its 200 day moving average price is $1,027.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.